

## Prior authorization requirement for injectable/infusible drugs: mepolizumab (Nucala) and reslizumab (Cinqair)

Published: Aug 16, 2018 - **State & Federal** / Medi-Cal Managed Care

Effective September 1, 2018, prior authorization (PA) requirements will change for injectable/infusible drugs mepolizumab (Nucala®) and reslizumab (Cinqair®). Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.

**Noncompliance with new requirements may result in denied claims.**

### PA requirements will be added to the following:

- Mepolizumab (Nucala) — injection, 1 mg (J2182)
- Reslizumab (Cinqair) — injection, 1 mg (J2786)

### To request PA, you may use one of the following methods:

- **Web:** <https://www.availability.com>
- **Fax:** 1-800-754-4708
- **Phone:**
  - o 1-888-831-2246 (Medi-Cal Managed Care)
  - o 1-877-273-4193 (Major Risk Medical Insurance Program)

Not all PA requirements are listed here. PA requirements are available to contracted providers through the Availity Portal (<https://www.availability.com>). Providers who are unable to access Availity may call us at **1-888-831-2246** (Medi-Cal Managed Care) or **1-877-273-4193** (Major Risk Medical Insurance Program) for PA requirements.

**URL:** <https://providernews.anthem.com/california/article/prior-authorization-requirement-for-injectableinfusible-drugs-mepolizumab-nucala-and-reslizumab-cinqair>

**Featured In:**

August 2018 Anthem Blue Cross Provider Newsletter - California

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross name and symbol are registered marks of the Blue Cross Association. Use of the Anthem Web sites constitutes your agreement with our Terms of Use.

---